Flush, Lyse, Operate
Part of paid clinical trials in Hanover, New Hampshire.
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Study ID
- NCT07592520
- Phase
- PHASE4
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Complicated Parapneumonic Effusion
- Empyema, Pleural
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intrapleural Saline with possible escalation to intraplerual alteplase and dornase. — DRUGThough intraplerual alteplase/ dornase alfa and normal saline have been established method to reduce complicated pleural infection sizes and rate of surgical interventions, with tPA/DNAse being the gold standards, there has not been a study comparing the two head to head. This trial's purpose is to function as pilot study as a foundation for a potential noninferiorrity trail comparing the two.
Study Details
The goal of this observational study is to learn if saline results in improvement for patients with infection of their plerual space. The main question it aims to answer is: What is the time to chest tube removal? Do these patients after need to escalate to fibrinolytics? Do these patients after need to escalate to surgery? Participants will: * Receive receive saline into their pleural space through an existing chest tube * If they fail to improve, which will be determined by fluid size after treatment or signs of persistent infection, they will receive fibrynolytics through an existing chest tube * If they fail to improve, which will be determined by fluid size after treatment or signs of persistent infection, they will be referred to surgery.
Key Dates
- Start date
- Apr 30, 2026
- Status verified
- May 2026
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: Intraplerual SalineAll patients will be in a single arm and escalated from intraplerual saline to tPA/DNAse followed by surgery as warranted based on protocol criteria.
Primary Outcome Measure
Time to chest tube removal [ Time Frame: From enrollment to removal- estimated up to 7 days. Once chest tube is placed, it will take 3 days for saline course to be completed and, if escalated, 3 days for intrapleural fibrinolytics, therefore may not be removed until after 7 days. ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dartmouth-Hitchcock Medical Center | Hanover | New Hampshire | 03756 | Jimmy Wang, MD (SUB_INVESTIGATOR) David Feller-Kopman, MD (SUB_INVESTIGATOR) |
Find similar trials in Hanover, NH
Related Studies
- Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or EmpyemaPHASE4 · Recruiting · University of North Carolina, Chapel Hill · New Haven, Connecticut
- Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and EmpyemasRecruiting · Vanderbilt University Medical Center · Sterling Heights, Michigan